PRIOR AUTHORIZATION REQUEST FORM
Ribociclib (Kisqali®)/ Advanced or metastatic breast cancer

DECLARATION OF THE INSURED PERSON

Section 1 : Information about the plan member and the patient			
Name of plan member	Insurance policy / certificate	Name of employer	
Name of patient	Date of birth (YYYY/MM/DD)	Telephone	
Address (number and street name)	City/Town	Province	Postal code

Section 2 : Other prescription drug insurance policies			
Do you have other prescription drug insurance?		❒ Yes	❒ No
If so, please answer the following:			
What type of plan is it?		❒ Private	❒ Public
Have you ever submitted a claim for this drug to the other insurer?		❒ Yes	❒ No
What is the status of the claim?	❒ Accepted	❒ Refused	❒ Under review
Did this insurer ask you to complete a prior authorization request?		❒ Yes	❒ No
If so, what is the status of the prior authorization request?	❒ Accepted	❒ Refused	❒ Under review

Please enclose acceptance or refusal documents, if applicable

Section 3 : Authorization to disclose personal information

I certify that the information in this prior authorization request is complete, accurate and true.

I authorize physicians and other health care professionals, medical, paramedical or clinical institutions, care coordinators, members of SSQ's Preferred Pharmacy Network (outside Quebec only) and any public or parapublic organization, including Régie de l 'assurance maladie du Québec, to disclose to SSQ, Life Insurance Company Inc. (SSQ) any of my relevant personal information including and without limitation, any medical information and medical evaluations in connection with the processing of this request. I hereby waive their confidentiality obligation and authorize them to disclose the requested information to SSQ. In addition, I authorize SSQ to disclose to the previously named third parties any of my relevant personal information including and without limitation, any medical information and medical evaluations in connection with the processing of this request.

Photocopies of this document have the same value as the original.

Signature of **patient** (parent/legal guardian) _____ Date _____

IMPORTANT :

All correspondence concerning this form will be sent to the address indicated in the participant's file.

Send us this duly completed form by mail or by fax to: 1-855-453-3942.

Telephone: 418-651-2588/1-800-380-2588 – Fax: 1-855-453-3942 Address: 2525 Laurier Blvd, P.O. Box 10500, Quebec City, QC G1V 4H6 /**ssq.ca**

PRIOR AUTHORIZATION REQUEST FORM
Ribociclib (Kisqali®)/ Advanced or metastatic breast cancer

DECLARATION OF THE PRESCRIBER

Section 4 : Information about the prescriber		
Name of prescriber	Specialty	License no.
Telephone	Fax	
I hereby certify that the information in this request is complete, true and accurate. Signature of **prescriber** _____ Date _____		

Section 5 : Drug covered by the authorization			
Name of drug	Pharmaceutical form	Strength	**Dosage** Dose: _____ Frequency of administration: _____
Type of request	❒ First request Complete section 6		❒ Continuation of treatment Complete section 7 Also complete section 6 if this is the first authorization requested from SSQ

PRIOR AUTHORIZATION REQUEST FORM
Ribociclib (Kisqali®)/ Advanced or metastatic breast cancer

IMPORTANT:

Please do not provide any genetic test results

Section 6 : Clinical information (first request)

Diagnosis

❒ Advanced or metastatic breast cancer in compliance with Health Canada approved indication

For informational purposes only:

KISQALI® is indicated by Health Canada in combination with:

- An aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR+) positive, human epidermal growth factor receptor 2 (HER2-) negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

  In pre/perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.

- Fulvestrant for the treatment of postmenopausal women with HR+, HER2- advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.

❒ Other, specify: _____

Complete the following information

❒ Post-menopausal ❒ Pre/perimenopausal

Actual value of the ECOG performance status

❒ 0 ❒ 1 ❒ 2 ❒ 3 ❒ 4

Administration of Kisqali®

Administered as first-line metastatic treatment? ❒ Yes ❒ No

❒ In combination with Letrozole

❒ In combination with Fulvestrant

❒ Other, specify: _____

_____

_____

Section 6 : Clinical information (first request) (cont'd)

Summary of previous trials or contraindications

Drug or other medical treatment	Reason for discontinuation	Duration of treatment
Name: ____________________ Dosage: ___________________	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _______________	From _______________ To _________________
Name: ____________________ Dosage: ___________________	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _______________	From _______________ To _________________
Name: ____________________ Dosage: ___________________	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _______________	From _______________ To _________________
Name: ____________________ Dosage: ___________________	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _______________	From _______________ To _________________
Name: ____________________ Dosage: ___________________	❒ Ineffectiveness ❒ Intolerance ❒ Contraindication ❒ Other, specify: _______________	From _______________ To _________________

Section 7 : Clinical information (continuation of treatment)

Information necessary to evaluate the response to treatment

The drug covered by the present authorization request was first taken on (YYYY-MM-DD): ____________________

Administration of Kisqali®

❒ In combination with Letrozole

❒ In combination with Fulvestrant

❒ Other, specify: _______________________

Positive clinical effects observed

Date treatment began (YYYY-MM-DD): __________________

❒ Absence of disease progression

❒ Other, specify: _______________________

Section 8 : Additional information